Conditions: Non-infectious Uveitis
Keywords: Quiescent uveitis intermediate uveitis panuveitis posterior uveitis uveitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 125
Healthy volunteers: no

Brief summary:
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.

Detailed description:

Arms:
arm 1: AIN457 300mg s.c weekly for 3 weeks then every 2 weeks arm 2: AIN457 300mg s.c at baseline and Week 2 then every 4 weeks arm 3: AIN457 150mg s.c at baseline and Week 2 then every 4 weeks arm 4: Placebo s.c weekly for 3 weeks then every 2 weeks

Interventions: intervention 1: AIN457 intervention 2: AIN457 intervention 3: AIN457 intervention 4: Placebo
Intervention descriptions: intervention 1: AIN457 300mg s.c weekly for 3 weeks then every 2 weeks intervention 2: AIN457 300mg s.c at baseline and Week 2 then every 4 weeks intervention 3: AIN457 150mg s.c at baseline and Week 2 then every 4 weeks intervention 4: Placebo s.c weekly for 3 weeks then every 2 weeks

Protocol document: